Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Top Page
Brainstorm Cell Therapeutics
(NASDAQ:BCLI)
Rating:40Underperform
Price Target:―
Positive Factors
FDA Clearance
FDA clearance for the upcoming P3b (ENDURANCE) study in amyotrophic lateral sclerosis (ALS) announced, positioning BrainStorm to acquire funds for the trial, including non-dilutive sources like a $15M grant under review.
Manufacturing Collaboration
The strategic collaboration with Minaris Advanced Therapies enhances US-based manufacturing capabilities and brings the scalability needed for NurOwn's complex autologous cell therapy.
Therapeutic Impact
NurOwn is the most advanced therapy in the ALS space, is safe, and has a history of positive therapeutic impact, making the trial crucial for patients and caregivers.
Negative Factors
Macroeconomic Factors
Pre-revenue Biotech is particularly susceptible to macroeconomic factors due to its reliance on capital and inherent uncertainty.
Market Conditions
Difficult market conditions, particularly for small/micro-cap stocks, and economic uncertainty continue to pressure broader markets.
Valuation Challenges
Valuations across much of the Biotech space have continued to pullback and reset, with reductions in price targets for multiple stocks.
Brainstorm Cell Therapeutics (BCLI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.37M
Dividend YieldN/A
Average Volume (3M)2.39M
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue GrowthN/A
EPS Growth62.35%
CountryUS
Employees27
SectorHealthcare
Sector Strength58
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding7,938,876
10 Day Avg. Volume523,886
30 Day Avg. Volume2,385,927
Financial Highlights & Ratios
PEG Ratio12.68
Price to Book (P/B)-297.88
Price to Sales (P/S)0.00
P/FCF Ratio-46.42
Enterprise Value/Market Cap96.23
Enterprise Value/Revenue876.04
Enterprise Value/Gross Profit-1.42K
Enterprise Value/Ebitda-14.69
Forecast
1Y Price Target
$6.00Price Target Upside445.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Brainstorm Cell Therapeutics Business Overview & Revenue Model
Company DescriptionBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
How the Company Makes MoneyBrainstorm Cell Therapeutics generates revenue through the development and commercialization of its proprietary cellular therapies. The company's primary revenue stream is expected to come from the sale or licensing of NurOwn, pending regulatory approval and successful commercialization. Additionally, Brainstorm may engage in strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other stakeholders to advance its clinical programs and expand its market reach. These partnerships may provide upfront payments, milestone payments, and royalties, contributing to the company's earnings. Other potential revenue sources include government grants and funding from non-profit organizations that support research in neurodegenerative diseases.
Brainstorm Cell Therapeutics Earnings Call Summary
Earnings Call Date:May 16, 2025
(Q1-2025)
| % Change Since: -5.17%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in regulatory clearance and clinical trial preparations for NurOwn, alongside promising biomarker research and development in the exosome program. However, financial constraints and the need for funding to initiate the trial were notable challenges.Q1-2025 Updates
Positive Updates
Regulatory Clearance for Phase 3b Trial
The U.S. FDA has cleared Brainstorm Cell Therapeutics to initiate the Phase 3b trial for NurOwn, marking a significant milestone in their ALS treatment development.
Strong Interest from Clinical Sites
Brainstorm is negotiating with approximately 15 leading clinical centers across the United States for their Phase 3b trial, highlighting strong interest and support from renowned ALS clinicians and researchers.
Positive Biomarker Research
Significant changes in biomarkers were observed in the study, showing NurOwn's potential multimodal mechanism of action, including neuroprotective and anti-inflammatory effects.
Exosome Program Progress
Promising preclinical data from Brainstorm's exosome program demonstrates therapeutic effects in models of lung disease, with active pursuit of strategic partnerships for clinical development.
Negative Updates
Financial Constraints and Funding Challenges
Brainstorm faces significant financial constraints, impacting their ability to execute the clinical trial without securing robust and sustainable cash flow.
Reliance on Funding for Trial Initiation
The company acknowledged the necessity to secure adequate funding before commencing the Phase 3b trial, highlighting the financial hurdles faced.
Company Guidance
During the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call, extensive guidance was provided regarding the company's strategic and operational plans. The company announced the U.S. FDA clearance to initiate a pivotal Phase 3b trial for their NurOwn technology, aimed at treating early-stage ALS patients, marking a significant regulatory milestone. Additionally, they plan to initiate manufacturing at the Tel Aviv Sourasky Medical Center, with a subsequent technology transfer to Pluri for expanded cleanroom facilities. The trial, named ENDURANCE, is designed under a Special Protocol Assessment (SPA) with the FDA to mitigate regulatory risks. Approximately 15 leading clinical centers across the U.S. are poised to participate in the trial, with ongoing negotiations for clinical trial agreements. The company also highlighted the financial constraints and ongoing efforts to secure strategic funding, including a $15 million non-dilutive grant under review. These initiatives underscore the company's commitment to developing innovative therapeutic options for ALS within a challenging financial environment.Brainstorm Cell Therapeutics Financial Statement Overview
Summary
Brainstorm Cell Therapeutics faces significant financial challenges, with ongoing losses and negative cash flows. Despite a slight improvement in equity, the company's financial stability is still at risk, requiring strategic changes to improve revenue and cash flow.Income Statement
Brainstorm Cell Therapeutics shows a significant net loss for multiple years with minimal revenue in 2024. The gross profit margin is 100% due to its small revenue covering costs, but net profit margins remain negative. The revenue growth rate is not meaningful due to zero revenue in previous years. Continued negative EBIT and EBITDA margins indicate ongoing operational challenges.25
Negative
Balance Sheet
The company has a fluctuating equity position, currently positive but previously negative. The debt-to-equity ratio is relatively low at 0.87, indicating some financial stability. However, the equity ratio is modest due to past negative equity, reflecting potential risk.30
Negative
Cash Flow
Operating cash flow remains negative, indicating insufficient cash generation from operations. Free cash flow is also negative, with a significant growth in free cash flow loss compared to past years. The operating cash flow to net income ratio is not meaningful due to consistent net losses.20
Very Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 849.00K | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 849.00K | -265.00K | -285.00K | -260.00K | -219.00K | EBIT |
| 0.00 | -21.44M | -24.82M | -24.54M | -31.68M | EBITDA |
| 0.00 | -16.93M | -23.99M | -24.28M | -31.46M | Net Income Common Stockholders |
| 11.62M | -17.19M | -24.28M | -24.46M | -31.81M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 187.00K | 1.30M | 2.98M | 22.09M | 41.94M | Total Assets |
| 1.83M | 4.21M | 8.45M | 29.28M | 51.26M | Total Debt |
| 720.00K | 672.00K | 4.09M | 5.08M | 7.22M | Net Debt |
| 533.00K | -628.00K | 3.32M | -13.78M | -30.61M | Total Liabilities |
| 9.60M | 9.07M | 11.47M | 9.94M | 15.79M | Stockholders Equity |
| -7.76M | -4.86M | -3.02M | 19.34M | 35.46M |
| Cash Flow | Free Cash Flow | |||
| -9.09M | -20.48K | -19.35M | -26.59M | -35.57M | Operating Cash Flow |
| -9.09M | -20.46M | -19.32M | -26.27M | -35.19M | Investing Cash Flow |
| 12.00K | 2.19M | 998.00K | 323.00K | -4.45M | Financing Cash Flow |
| 7.97M | 18.98M | 238.00K | 6.97M | 76.94M |
Brainstorm Cell Therapeutics Technical Analysis
Negative
1.10
Price Trends
1.10
Negative
1.39
Negative
1.89
Negative
Market Momentum
<0.01
Negative
44.47
Neutral
40.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCLI, the sentiment is Negative. The current price of 1.1 is below the 20-day moving average (MA) of 1.17, below the 50-day MA of 1.10, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 44.47 is Neutral, neither overbought nor oversold. The STOCH value of 40.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCLI.
Brainstorm Cell Therapeutics Risk Analysis
Brainstorm Cell Therapeutics disclosed 64 risk factors in its most recent earnings report. Brainstorm Cell Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Brainstorm Cell Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.41B | 3.27 | -45.10% | 3.29% | 16.81% | 0.02% | |
52 Neutral | $15.71M | ― | -195.46% | ― | -29.46% | 2.71% | |
41 Neutral | $8.43M | 49.73 | -18.56% | ― | -100.00% | ― | |
40 Underperform | $9.37M | ― | 234.90% | ― | ― | 62.35% | |
34 Underperform | $8.88M | ― | -538.87% | ― | ― | -26.02% | |
| $9.08M | ― | -302.69% | ― | ― | ― | ||
| $1.87M | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
BCLI
Brainstorm Cell Therapeutics
1.10
-5.35
-82.95%
GTBP
GT Biopharma
2.84
-0.08
-2.74%
GNPX
Genprex
0.29
-1.92
-86.88%
APM
Aptorum Group
1.15
-3.43
-74.89%
LYRA
Lyra Therapeutics
11.34
-2.18
-16.12%
CDT
Conduit Pharmaceuticals
2.33
-2,532.67
-99.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.